CA2827648A1 - Tricyclic inhibitors of kinases - Google Patents

Tricyclic inhibitors of kinases Download PDF

Info

Publication number
CA2827648A1
CA2827648A1 CA2827648A CA2827648A CA2827648A1 CA 2827648 A1 CA2827648 A1 CA 2827648A1 CA 2827648 A CA2827648 A CA 2827648A CA 2827648 A CA2827648 A CA 2827648A CA 2827648 A1 CA2827648 A1 CA 2827648A1
Authority
CA
Canada
Prior art keywords
pyrimido
pyrimidin
amino
imidazo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2827648A
Other languages
English (en)
French (fr)
Inventor
Yunsong Tong
Thomas D. Penning
Alan Florjancic
Julie Miyashiro
Keith W. Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA2827648A1 publication Critical patent/CA2827648A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2827648A 2011-02-28 2012-02-27 Tricyclic inhibitors of kinases Abandoned CA2827648A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161447405P 2011-02-28 2011-02-28
US61/447,405 2011-02-28
PCT/US2012/026685 WO2012161812A1 (en) 2011-02-28 2012-02-27 Tricyclic inhibitors of kinases

Publications (1)

Publication Number Publication Date
CA2827648A1 true CA2827648A1 (en) 2012-11-29

Family

ID=46000328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827648A Abandoned CA2827648A1 (en) 2011-02-28 2012-02-27 Tricyclic inhibitors of kinases

Country Status (11)

Country Link
US (1) US8710065B2 (enExample)
EP (1) EP2681221B1 (enExample)
JP (1) JP5886326B2 (enExample)
CN (1) CN103703005A (enExample)
AR (1) AR085502A1 (enExample)
CA (1) CA2827648A1 (enExample)
ES (1) ES2587514T3 (enExample)
MX (1) MX340402B (enExample)
TW (1) TWI532742B (enExample)
UY (1) UY33925A (enExample)
WO (1) WO2012161812A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154191A1 (en) * 2014-04-10 2015-10-15 Dalhousie University Treatment of parkinson's disease through arfgap1 inhibition using substituted piperazine derivatives

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
JPWO2015029447A1 (ja) * 2013-08-30 2017-03-02 興和株式会社 光学活性カルビノール化合物の製造方法
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CN107072970B (zh) * 2014-08-29 2021-05-25 得克萨斯州大学系统董事会 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP7240784B2 (ja) * 2016-11-16 2023-03-16 上海瑛派▲薬▼▲業▼有限公司 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物
ES2902050T3 (es) * 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019011228A1 (zh) * 2017-07-10 2019-01-17 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CA3071795A1 (en) 2017-08-04 2019-02-07 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
CN107821390A (zh) * 2017-10-13 2018-03-23 南京扬子鸿利源化学品有限责任公司 一种甲基磺草酮油悬浮剂及其制备方法
PT3712150T (pt) 2017-11-01 2024-08-22 Wuxi Biocity Biopharmaceutics Co Ltd Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Wee1阻害剤としてのピリミドピラゾロン類誘導体及びその使用
AR117929A1 (es) 2019-02-01 2021-09-01 Bayer Ag Compuestos de 1,2,4-triazin-3(2h)-ona
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US12291536B2 (en) 2019-04-30 2025-05-06 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of Wee1 inhibitor compound and use thereof
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
CN114502559B (zh) * 2019-10-16 2024-02-02 上海瑛派药业有限公司 二氢咪唑并嘧啶并嘧啶酮类化合物
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
TWI823255B (zh) * 2021-02-19 2023-11-21 大陸商微境生物醫藥科技(上海)有限公司 作為Wee-1抑制劑的稠環化合物
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4332104A4 (en) * 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
JP2024543405A (ja) * 2021-11-09 2024-11-21 ハンジョウ グルバイオ ファーマシューティカル カンパニー リミテッド Wee1プロテインキナーゼ分解剤及びその使用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
WO2025188106A1 (ko) * 2024-03-08 2025-09-12 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004017494D1 (de) 2003-07-25 2008-12-11 Novartis Ag Inhibitoren von p-38-kinase
US20050070554A1 (en) * 2003-08-27 2005-03-31 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
WO2008072779A1 (ja) * 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
US8329711B2 (en) * 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
ES2430053T3 (es) 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedimiento para producir derivados de bicicloanilina
CA2745970A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154191A1 (en) * 2014-04-10 2015-10-15 Dalhousie University Treatment of parkinson's disease through arfgap1 inhibition using substituted piperazine derivatives
AU2015245901B2 (en) * 2014-04-10 2017-05-25 Dalhousie University Treatment of Parkinson's disease through ArfGAP1 inhibition using substituted piperazine derivatives
US10300055B2 (en) 2014-04-10 2019-05-28 Dalhousie University Treatment of parkinson's disease through ARFGAP1 inhibition

Also Published As

Publication number Publication date
MX340402B (es) 2016-07-07
CN103703005A (zh) 2014-04-02
JP2014506929A (ja) 2014-03-20
TW201247675A (en) 2012-12-01
EP2681221B1 (en) 2016-05-18
MX2013009873A (es) 2014-03-12
US20120220572A1 (en) 2012-08-30
JP5886326B2 (ja) 2016-03-16
ES2587514T3 (es) 2016-10-25
WO2012161812A1 (en) 2012-11-29
AR085502A1 (es) 2013-10-09
UY33925A (es) 2012-09-28
EP2681221A1 (en) 2014-01-08
TWI532742B (zh) 2016-05-11
US8710065B2 (en) 2014-04-29

Similar Documents

Publication Publication Date Title
US8710065B2 (en) Tricyclic inhibitors of kinases
US9051327B2 (en) Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US8716297B2 (en) Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US9718821B2 (en) Pyridopyrimidinone inhibitors of kinases
EP2569316B1 (en) Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
EP2454257B1 (en) Pyrrolopyridine inhibitors of kinases
US9181239B2 (en) Pyridopyrimidinone inhibitors of kinases
CA2824871A1 (en) Bicyclic inhibitors of alk
CA2794859A1 (en) Phthalazin-(2h)-one inhibitors of kinases
CA2794861A1 (en) Pyrrolopyrazinone inhibitors of kinases
HK1196370A (en) Tricyclic inhibitors of kinases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180227